ArticleInfection and drug resistance2020
Reversal of
Article in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- CRISPR-Cas systems in combating antimicrobial resistance: which system to choose? A systematic review.World journal of microbiology & biotechnology · 2025Pooled it
- CRISPR-cas systems in pharmacology: functional pharmacogenomics, drug screening, resistance, and therapeutic translation.Functional & integrative genomics · 2026Review
- Phage and CRISPR based precision antimicrobials: a dual strategy against multidrug-resistant bacteria.Molecular biology reports · 2026Review
- CRISPR/Cas system as a novel therapeutic strategy to combat multi-drug-resistant bacteria.Archives of microbiology · 2026Review
- CRISPR-based gene editing for antimicrobial resistance control in human medicine.Archives of microbiology · 2026Review
- Nanocarrier-mediated CRISPR-Cas delivery: a novel approach against antibiotic-resistant superbugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Colistin Resistance in Gram-Negative Bacteria: Mechanisms, Transmission, and Novel Intervention Strategies.Microorganisms · 2026Review
- Epigenetic regulation and antimicrobial resistance: functional roles of DNA methylation.FEMS microbiology reviews · 2026Review
- Article
- CRISPR-Cas opens a new era of antimicrobial therapy as a powerful gene editing tool.World journal of microbiology & biotechnology · 2025Review
- Colistin resistance in the era of antimicrobial resistance: challenges and strategic countermeasures.Folia microbiologica · 2025Review
- Antibiotic-ResistantMicroorganisms · 2025Review
- Role of CRISPR-Cas system as a new approach in fighting the antimicrobial resistance of bacterial and viral pathogens.Infectious diseases & immunity · 2025Review
- Lipid Nanoparticle-Mediated CRISPR-Cas13a Delivery for the Control of Bacterial Infection.Advanced healthcare materials · 2025Article
- Role of CRISPR-Cas systems and anti-CRISPR proteins in bacterial antibiotic resistance.Heliyon · 2024Review
- CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Review
- Resensitizing tigecycline- and colistin-resistantMicrobiology spectrum · 2024Article
- Recent Advances in Understanding the Molecular Mechanisms of Multidrug Resistance and Novel Approaches of CRISPR/Cas9-Based Genome-Editing to Combat This Health Emergency.International journal of nanomedicine · 2024Review
- CRISPR-Cas Systems in the Fight Against Antimicrobial Resistance: Current Status, Potentials, and Future Directions.Infection and drug resistance · 2024Review
- Targeted elimination of Vancomycin resistance gene vanA by CRISPR-Cas9 system.BMC microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe plasmid-borne mobilized colistin resistance gene (
methodsTwo sgRNAs specific to
resultsIn this study, we constructed the high copy number plasmid pUC19-
conclusionWe presented a method that only one plasmid-mediated CRISPR-Cas9 system can be used to efficiently resensitize
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.